CEP-14083

• Description:

  CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC50 value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK) . CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma[1][2].

• UNSPSC:

  12352005

• Target:

  Anaplastic lymphoma kinase (ALK) ; Insulin Receptor; Tie; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cep-14083.html

• Smiles:

  CN1N=C2CCC3=C4N (C5=CC=C (C=C5C4=C (CNC6=O) C6=C3C2=C1) NC (N (C7=CC=CC=C7) C) =O) CCC

• Molecular Formula:

  C31H30N6O2

• Molecular Weight:

  518.61

• References & Citations:

  [1]Puig de la Bellacasa R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013 Apr;2 (2) :72-86.|[2]Marzec M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) . Proc Natl Acad Sci U S A. 2008 Dec 30;105 (52) :20852-7.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  856692-39-2